| Date: | 2006-11-27 |
| Acquiring pharma company: | Crucell (The Netherlands) |
| Acquired biotech company: | SBL Vaccine (Sweden) |
| Amount: | Euro39.4 million |
| Terms of the agreement: | |
| Other: | The operation enables Crucell to establish itself in Scandinavia and to acquire a company with its own vaccine production capacities and a sales and distribution circuit. It also enables Crucell to strengthen its portfolio of "special" vaccines, with the arrival of Dukoral®, a vaccine against cholera and traveller's diarrhoea, already authorised in over fifty countries. |
